Fenretinide

Drug Profile

Fenretinide

Alternative Names: 4 HPR; HPR; MCNR 1967; RT-101; ST-602

Latest Information Update: 23 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ortho-McNeil
  • Developer Ortho-McNeil; ReVision Therapeutics
  • Class Antineoplastics; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Plasma retinol-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Basal cell cancer; Bladder cancer; Breast cancer; Dry age-related macular degeneration; Glioma; Neuroblastoma; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 23 Jan 2015 Discontinued - Phase-II for Dry age-related macular degeneration in USA (PO)
  • 18 Oct 2010 Final efficacy data from a phase IIb trial in Age-related macular degeneration released by ReVision Therapeutics
  • 15 Apr 2009 Fenretinide received Fast Track designation for Age-related macular degeneration [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top